摘要
目的:探讨乳腺癌患者钼靶X线表现与癌基因蛋白表达之间的相关性.方法:收集术前行钼靶X线检查且临床资料完整的乳腺癌患者83例,用链霉菌抗生物蛋白-过氧化酶免疫组织化学法(S-P法)检测c-erbB-2,ER,PR基因的表达,分析钙化、结构扭曲、肿块征的影像表现与c-erbB-2,雌激素受体(ER),孕激素受体(PR)的关系.结果:钼靶X线表现:单纯肿块39例(47.0%),单纯钙化17例(20.5%),结构扭曲13例(15.7%),肿块+钙化9例(10.8%),扭曲+钙化5例(6.0%).病变有钙化组c-erbB-2基因的阳性表达率71.0%(22/31),无钙化组的阳性表达率42.3%(22/52),二者之间的差别有统计学意义(χ2=6.040,P=0.01).结构扭曲组ER的阳性表达率28.6%(4/18),低于非结构扭曲组ER的阳性表达率47.7%(31/65),二者的差别有统计学意义(Fishers精确检验,P=0.045).肿块组PR阳性表达率27.1%(13/48)低于非肿块组PR的阳性表达率48.6%(17/35),二者的差别有统计学意义(χ2=4.049,P=0.044).结论:乳腺癌钼靶X线征象与基因蛋白的异常表达有一定的相关性.
AM ： To explore the relationship between mammo- graphic signs and expression of the protein factors in breast can- cer. METHODS： Eighty-three patients with breast cancer were enrolled in this study. The expression of c-erbB-2, ER, PR was examined by S-P immunohistochemical technique. The relation- ship between the mammographic manifestations and the expression of protein factors was analyzed. RESULTS ： Mammographic ma- nifestation demonstrated that the number of patients with only mass was 39 （47.0%） , only calcification 17 （20.5%） , struc- tural disorder 13 （ 15.7% ） , mass plus calcification 9 （ 10.8% ） , and structural disorder plus calcification 5 （6.0%）. The positive expression rate of c-erbB-2 in the group with calcification was 71.0% （22/31）, without calcification was 42.3% （22/52） , and the difference was statistically significant （X^2= 6. 040, P = 0.01 ）. The positive expression rate of ER in the group with struc- tural disorder was 28.6% （4/18）, without structural disorder was 47.7% （31/65） , and the difference was statistically signifi- cant （ Fisher＇s exact test, P = 0. 045 ）. The positive expression rate of PR in the group with mass was 27.1% （ 13/48）, without mass was 48.6% （ 17/35 ）, and the difference was statistically significant （X^2= 4. 049, P = 0. 044 ）. CONCLUSION ： The mammographic manifestations of breast cancer has some kind of correlation with the expression of protein factors.
出处
《第四军医大学学报》
CAS
北大核心
2007年第21期1996-1999,共4页
Journal of the Fourth Military Medical University
基金
深圳市科技局资助项目(200404025
200603179)
深圳市医学重点专科资助(2004052)
